This summer, Hugues Péribère, creator and director of the company Overseed, registered at Agreen Lab'O in Orléans, announced that he was ready to market the first French cannabis-based medicines.
The company, which employs ten employees as well as ten external experts, has been working since 2020 to select the best plants in order to transform them into sublingual oil. Medications intended to relieve (and not cure) patients suffering from various chronic pains (read below), in therapeutic failure.
Fin 2025 ?
In October, cautious, and still not seeing the government texts coming, Hugues Péribère, also vice-president of Santé France Cannabis, preferred to communicate on a release during 2025. Today, he hopes that this will be the case at the end of 2025!
So many years to go without turnover, thanks to fundraising (the company raised 6.7 million euros this summer). He plans to carry out another one at the end of 2025, “but it will take positive signs”.
Why such a delay? Everything is due, he explains, to French political instability and the confusion of some, to the Interministerial Mission for the Fight against Drugs and Addictive Behaviors, between medical and recreational cannabis, “while this does not not enter their area of expertise!”
Related News :